No Data
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $43
UBS analyst Trung Huynh maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and adjusts the target price from $52 to $43.According to TipRanks data, the analyst has a success rate of 75.5%
Express News | Bristol-Myers Squibb Co : UBS Cuts Target Price to $43 From $47
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $41
Barclays analyst Carter Gould maintains $Bristol-Myers Squibb(BMY.US)$ with a hold rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate of 57.7%
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Cuts Target Price to $37
Morgan Stanley analyst Terence Flynn maintains $Bristol-Myers Squibb(BMY.US)$ with a sell rating, and adjusts the target price from $40 to $37.According to TipRanks data, the analyst has a success
Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY)
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating
Bristol-Myers Squibb (BMY) has an average hold rating and a price target range of $37 to $75, according to analysts polled by Capital IQ.Price: 41.08, Change: -0.04, Percent Change: -0.10